No, but we check manually and independently the Alpha list twice to detect those variants which might be not detected by our standardized pipeline but present at lower percentage and potentially associated with secondary resistance to approved drugs.

Additionally, if we detect a damaging variant not in the Alpha list, we also do a manual check but we don’t confirm by an alternative technology.